AstraZeneca secures US FDA approval for Brilinta for long term use
The regulatory authority has approved Brilinta tablets at a new dose that could be taken along with aspirin beyond a year of heart attack, reported Reuters. In July
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
The approval is based on four trials of patients receiving emetogenic chemotherapy, including cisplatin, carboplatin and anthracycline/cyclophosphamide-based regimens. Varubi is a selective and competitive antagonist of human substance
It enables preclinical development of Ocata’s proprietary photoreceptor progenitor product for the treatment of retinal degenerative diseases, such as retinitis pigmentosa (RP) and photoreceptor dystrophies. Ocata chief scientific